Biotech Values

[hptaxis]

Revance's RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines
http://investors.revance.com/releasedetail.cfm?ReleaseID=1050685

- Highly statistically significant results on primary composite endpoint achieved at Week 4 -
- RT002 delivered highly statistically significant reduction in severity of glabellar lines at Week 24 -
- If approved, RT002 could represent a new, next-generation, long-acting neuromodulator -
- Revance to host conference call at 8:00 am ET today -